Analysed TURN THERAPEUTICS INC (TTRX:NASDAQ) News Sources
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
09-02-2026
yahoo.com
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
17-02-2026
yahoo.com
Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy
02-03-2026
marketbeat.com
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
24-03-2026
yahoo.com
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
31-03-2026
yahoo.com
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
11-05-2026
yahoo.com
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
18-05-2026
yahoo.com
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
27-05-2026
yahoo.com
What is the current price of TURN THERAPEUTICS INC (TTRX:NASDAQ)?
The current price of TURN THERAPEUTICS INC (TTRX:NASDAQ) is $6.045.
TURN THERAPEUTICS INC (TTRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of TURN THERAPEUTICS INC (TTRX:NASDAQ) since the previous trading day is $0.185.
TURN THERAPEUTICS INC (TTRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of TURN THERAPEUTICS INC (TTRX:NASDAQ) since the previous trading day is 3.157%.
What is the most recent average sentiment score for TURN THERAPEUTICS INC (TTRX:NASDAQ)?
The most recent average sentiment score for TURN THERAPEUTICS INC (TTRX:NASDAQ) is 84 out of 100.
What is the most recent average sentiment for TURN THERAPEUTICS INC (TTRX:NASDAQ)?
The most recent sentiment for TURN THERAPEUTICS INC (TTRX:NASDAQ) is .
SEC-8K** Filing Available For TURN THERAPEUTICS INC (TTRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.